Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Compliance with antipsychotic drug treatment: influence of side effects.

Fleischhacker WW, Meise U, Günther V, Kurz M.

Acta Psychiatr Scand Suppl. 1994;382:11-5.

PMID:
7916523
2.

Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.

Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D.

J Clin Psychiatry. 2000 May;61(5):382-6.

PMID:
10847315
3.

Predictors of noncompliance in patients with schizophrenia.

Perkins DO.

J Clin Psychiatry. 2002 Dec;63(12):1121-8. Review.

PMID:
12523871
4.

Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives.

Silva RR, Muñoz DM, Daniel W, Barickman J, Friedhoff AJ.

J Clin Psychiatry. 1996 Mar;57(3):129-35.

PMID:
8617698
5.

[Ten years of clinical experience with clozapine about 170 patients].

Levoyer D, Martinet JP, Badiche A, Millet B.

Encephale. 2004 May-Jun;30(3):285-95. French.

PMID:
15235527
6.

Pharmacogenetics in psychosis.

Collier DA.

Drug News Perspect. 2003 Apr;16(3):159-65. Review.

PMID:
12819814
7.

Weight gain induced by clozapine.

Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW.

Eur Neuropsychopharmacol. 1995 Dec;5(4):437-40.

PMID:
8998394
9.

Optimizing treatment with clozapine.

Conley RR.

J Clin Psychiatry. 1998;59 Suppl 3:44-8. Review.

10.

Clozapine maintenance therapy in schizophrenia.

Gaszner P, Makkos Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):465-9.

PMID:
15093952
11.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

12.

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

Kopala LC.

Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S11-8. Review.

PMID:
9352341
13.

Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.

Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D, Naber D.

Eur Psychiatry. 2004 Nov;19(7):415-22.

PMID:
15504648
14.

Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.

Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW.

J Clin Psychiatry. 2004 Sep;65(9):1211-8.

PMID:
15367047
15.

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.

Ulrich S, Neuhof S, Braun V, Meyer FP.

Int Clin Psychopharmacol. 1999 Jul;14(4):219-28.

PMID:
10468314
16.

Optimizing clozapine treatment.

Naber D.

J Clin Psychiatry. 1999;60 Suppl 12:35-8. Review.

17.

Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.

Holzinger A, Loffler W, Muller P, Priebe S, Angermeyer MC.

J Nerv Ment Dis. 2002 Sep;190(9):597-603.

PMID:
12357093
18.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
19.

Subjective experience and mental side-effects of antipsychotic treatment.

Gerlach J, Larsen EB.

Acta Psychiatr Scand Suppl. 1999;395:113-7.

PMID:
10225340
20.

Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.

Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW.

Am J Psychiatry. 1999 Apr;156(4):631-3.

PMID:
10200746

Supplemental Content

Support Center